Skip to main contentAI and Advanced
/
SUVEN · NSEBSE SENSEX74,358.11+0.03%BSE |
NIFTY 5023,264.45+0.20%NSE |
NIFTY BANK56,115.35-0.31%NSE |
NIFTY IT29,037.75-0.17%NSE |
NIFTY AUTO27,166.8+1.02%NSE |
NIFTY FMCG45,624.35+0.14%NSE |
NIFTY PHARMA26,478.9+1.27%NSE |
NIFTY 50022,637.3+0.47%NSE |
SU
NSE · Equity shares · Biotechnology & Drugs7.55 · 2.24%
Suven Life Sciences SUVEN
NSE:INR 344
BSE:INR 343.9
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SUVEN
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 336.45
Day rangeINR 324 — INR 342
52-week rangeINR 124.11 — INR 403.35
Volume5.21 L
Market cap8,416.09
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)7.11
Net Income (INR Cr)-276.34
Rev Growth (5 Year %)-12
Book Value22.42
EPS-12.13
Price/BV15.34Computed
Research path: Interpret Suven Life Sciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SUVENSuven Life Sciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 624.21 | 135.18 | 284.9 |
| Cash Equivalents | 329.18 | Not available | Not available |
| Other Liabilities Total | 1.92 | 1.71 | 1.35 |
| Accrued Expenses | 1.52 | 1.64 | Not available |
| Common Stock Total | 26.37 | 21.81 | 21.81 |
| Other Current Assets Total | 21.34 | 0 | 0.05 |
| Total Assets | 624.21 | 135.18 | 284.9 |
| Current Portof LT Debt/Capital Leases | 4.55 | 0 | 0.71 |
| Cash | 8.28 | 15.03 | 14.93 |
| Total Equity | 591.4 | 109.99 | 270.04 |
| Long Term Investments | 0.88 | Not available | Not available |
| Retained Earnings(Accumulated Deficit) | 565.03 | -556.04 | -396.51 |
| Total Common Shares Outstanding | 26.37 | 21.81 | 21.81 |
| Tangible Book Valueper Share Common Eq | 22.42 | 5.04 | 12.37 |
| Total Liabilities | 32.81 | 25.2 | 14.86 |
| Total Debt | 16.69 | 0 | 0.71 |
| Short Term Investments | 180.65 | 44.98 | 224.94 |
| Cashand Short Term Investments | 518.11 | 60 | 239.87 |
| Total Receivables Net | 7.16 | 14.23 | 15.46 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 5.21 | 1.41 | 3.49 |
| Property/Plant/Equipment Total-Net | 76.45 | 59.48 | 28.01 |
| Total Current Liabilities | 18.75 | 23.49 | 13.52 |
| Total Inventory | 0.1 | 0.24 | 0.71 |
| Accounts Payable | 4.81 | 5.23 | 2.07 |
| Other Currentliabilities Total | 7.87 | 16.62 | 10.74 |
| Total Long Term Debt | 12.14 | 0 | 0 |
| Intangibles Net | 0.14 | 0.18 | 0.2 |
| Note Receivable-Long Term | 0.04 | 0 | 0.01 |
| Total Current Assets | 546.71 | 75.47 | 256.67 |
| Capital Lease Obligations | 12.14 | Not available | 0 |
| Accumulated Depreciation Total | Not available | -52.94 | -49.25 |
| Other Equity Total | Not available | -2.57 | -2.04 |
| Prepaid Expenses | Not available | 1 | 0.59 |
| Additional Paid-In Capital | Not available | 646.78 | 646.78 |
| Property/Plant/Equipment Total-Gross | Not available | 112.41 | 77.26 |
| Other Long Term Assets Total | Not available | 0.05 | 0.02 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %28.51
Margins
Operating Margin 12m-4,077.7
Operating Margin 5y Avg-1,646.2
Net Profit Margin 12m-3,884.13
Net Profit Margin 5y-1,538.79
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio1183.70
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk61.98
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 65.47%
- FII
- 0.48%
- MF
- 0.01%
- Other
- 34.04%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 13 June 2025Market news · 13 Jun 2025, 6:45 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Sree Rayalaseema Hi-Strength Hypo, Nava, Rainbow Children's Medicare, Suven Life Sciences, and Privi Speciality Chemicals.
<span class='webrupee'>₹</span>120 to <span class='webrupee'>₹</span>238: This small-cap pharma stock zooms nearly 100% in just 22 sessions. Are you holding it?Market news · 4 Jun 2025, 11:59 am
Suven Life Sciences shares have surged 98.3% from ₹ 120 to ₹ 238 over 22 trading sessions, driven by a recent ₹ 857 crore fundraising for R&D. Despite widening losses, investor optimism remains strong due to the company's CNS-focused drug pipeline and long-term growth potential.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 25 April 2025Market news · 25 Apr 2025, 6:38 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —Samhi Hotels, Suven Life Sciences, Thangamayil Jewellery, Transport Corporation of India, and Sundaram Finance Holdings
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Dec 11Market news · 11 Dec 2024, 7:16 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Gabriel India, Suven Life Sciences, GHCL, Elecon Engineering, and Gokaldas Exports
Top Stock Recommendations: Osho Krishan of Angel One suggests buying Suven Life Sciences, and Sutlej Textiles todayMarket news · 27 Jun 2024, 10:00 am
Top Stock Recommendations: Osho Krishan, Sr. Analyst, Technical & Derivatives of Angel One, recommends buying Suven Life Sciences Ltd, and Sutlej Textiles and Industries Ltd today.
Buy or sell: Vaishali Parekh recommends three stocks to buy today — February 7Market news · 7 Feb 2024, 6:12 am
Buy or sell stocks: Vaishali Parekh has recommended three stocks to buy today — Suven Life Sciences, Coforge, and India Cements
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- annual General MeetingEGM
Rusaka Markets Community
Discussion and sentiment for Suven Life Sciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SUVEN
- BSE Code
- 530239
Questions
Stock FAQ
What is the symbol and ISIN of Suven Life Sciences?
Suven Life Sciences has the symbol SUVEN and ISIN - INE495B01038.
What is the current price of Suven Life Sciences?
Suven Life Sciences is currently trading at INR 344.00.
What are the year high and year low of Suven Life Sciences?
Suven Life Sciences has a year high of INR 403.35 and a year low of INR 124.11.
What is the market capitalization of Suven Life Sciences?
Suven Life Sciences has a market capitalization of INR 8,416.09 crore.
What is the P/E ratio of Suven Life Sciences?
Suven Life Sciences has a P/E ratio of NA.
What is the dividend yield of Suven Life Sciences?
Suven Life Sciences has a dividend yield of 0.00%.
How is the financial performance of Suven Life Sciences based on revenue, net income, and EPS?
Suven Life Sciences has revenue of INR 7.11 crore, net income of INR -276.34 crore, and EPS of INR -12.29.
What is the book value of Suven Life Sciences?
Suven Life Sciences has a book value of INR 22.42.
What is the debt-to-equity ratio of Suven Life Sciences?
Suven Life Sciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Suven Life Sciences?
Suven Life Sciences has a price-to-book ratio of 15.34 and a price-to-sales ratio of 1183.70.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.